keyword
MENU ▼
Read by QxMD icon Read
search

asthma biologics

keyword
https://www.readbyqxmd.com/read/27908911/biological-treatment-is-approved-for-severe-eosinophilic-asthma
#1
Susan Mayor
No abstract text is available yet for this article.
November 30, 2016: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/27906698/ige-and-eosinophils-as-therapeutic-targets-in-asthma
#2
Tanvi R Patel, Sanjiv Sur
PURPOSE OF REVIEW: Asthma is a chronic inflammatory disorder characterized by reversible airflow obstruction, which is being more widely recognized as a broad-spectrum disease that encompasses multiple patient characteristics and pathophysiologic mechanisms. Suboptimal asthma control leads to increasing burden of healthcare costs and loss of productivity to society. Biologic therapies targeted at IgE and eosinophils can be used in poorly controlled allergic and eosinophilic asthma, respectively...
November 30, 2016: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27905186/severe-asthma-current-management-targeted-therapies-and-future-directions-a-roundtable-report
#3
REVIEW
Vanessa M McDonald, Steven Maltby, Helen K Reddel, Gregory G King, Peter A B Wark, Lorraine Smith, John W Upham, Alan L James, Guy B Marks, Peter G Gibson
Asthma is a chronic respiratory disease characterized by respiratory symptoms, airway inflammation, airway obstruction and airway hyper-responsiveness. Asthma is common and directly affects 10% of Australians, 1-5% of adults in Asia and 300 million people worldwide. It is a heterogeneous disorder with many clinical, molecular, biological and pathophysiological phenotypes. Current management strategies successfully treat the majority of patients with asthma who have access to them. However, there is a subset of an estimated 5-10% of patients with asthma who have severe disease and are disproportionately impacted by symptoms, exacerbations and overall illness burden...
November 30, 2016: Respirology: Official Journal of the Asian Pacific Society of Respirology
https://www.readbyqxmd.com/read/27902981/calcitriol-reduces-eosinophil-necrosis-which-leads-to-the-diminished-release-of-cytotoxic-granules
#4
Caroline Ethier, Yingqi Yu, Lisa Cameron, Paige Lacy, Francis Davoine
BACKGROUND: Asthma severity and eosinophilia correlate with a deficiency in vitamin D and its active metabolite calcitriol. Calcitriol modulates numerous leukocyte functions, but its effect on eosinophils is not fully understood. We postulated that calcitriol exerts a direct effect on eosinophil biology by modulating cell survival. METHODS: Purified peripheral blood eosinophils from atopic donors were incubated in the presence of calcitriol for up to 14 days with or without IL-5...
December 1, 2016: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/27889330/use-of-biologics-to-treat-acute-exacerbations-and-manage-disease-in-asthma-copd-and-ipf
#5
REVIEW
Lynne A Murray, Chris Grainge, Peter A Wark, Darryl A Knight
A common feature of chronic respiratory disease is the progressive decline in lung function. The decline can be indolent, or it can be accelerated by acute exacerbations, whereby the patient experiences a pronounced worsening of disease symptoms. Moreover, acute exacerbations may also be a marker of insufficient disease management. The underlying cause of an acute exacerbation can be due to insults such as pathogens or environmental pollutants, or the cause can be unknown. For each acute exacerbation, the patient may require medical intervention such as rescue medication, or in more severe cases, hospitalization and ventilation and have an increased risk of death...
November 24, 2016: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27876361/beneficial-effects-of-galectin-9-on-allergen-specific-sublingual-immunotherapy-in-a-dermatophagoides-farinae-induced-mouse-model%C3%A2-of-chronic-asthma
#6
Masaki Ikeda, Shigeki Katoh, Hiroki Shimizu, Akira Hasegawa, Katsuyo Ohashi-Doi, Mikio Oka
BACKGROUND: Allergen-specific sublingual immunotherapy is a potential disease-modifying treatment for allergic asthma. Galectin-9 (Gal-9), a β-galactoside-binding protein with various biologic effects, acts as an immunomodulator in excessive immunologic reactions by expanding regulatory T cells (Treg) and enhancing transforming growth factor (TGF)-β signaling. We investigated the efficacy of sublingually administered Gal-9 as an adjuvant to a specific allergen in a Dermatophagoides farinae (Df)-induced mouse model of chronic asthma...
November 19, 2016: Allergology International: Official Journal of the Japanese Society of Allergology
https://www.readbyqxmd.com/read/27871876/disaggregating-asthma-big-investigation-vs-big-data
#7
Danielle Belgrave, John Henderson, Angela Simpson, Iain Buchan, Christopher Bishop, Adnan Custovic
We are facing a major challenge in bridging the gap between identifying subtypes of asthma, to understanding causal mechanisms, and translating this knowledge into personalized prevention and management strategies. In recent years, "big data" has been sold as a panacea for generating hypotheses and driving new frontiers of healthcare; the idea that the data must and will speak for themselves is fast becoming a new dogma. One of the dangers of ready accessibility of healthcare data and computational tools for data analysis is that the process of data mining may become uncoupled from the scientific process of clinical interpretation, understanding the provenance of the data and external validation...
November 18, 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27870665/near-fatal-asthma-a-heterogeneous-clinical-entity
#8
José Serrano-Pariente, Vicente Plaza
PURPOSE OF REVIEW: The aims of the present review were to describe the heterogeneous nature of near-fatal asthma (NFA) and to summarize the distinctive phenotypes identified in this subtype of asthma. RECENT FINDINGS: Clinical, physiological, and histological studies have shown a large number of triggers, pathological mechanisms, and risk factors associated with NFA. Based on the demographic and clinical characteristics of the patients, the circumstances surrounding the asthma exacerbation and some distinctive features of the disease, several clinical profiles of asthma patients with NFA have been described...
November 18, 2016: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27867663/dry-powder-inhalers-a-focus-on-advancements-in-novel-drug-delivery-systems
#9
REVIEW
Piyush Mehta
Administration of drug molecules by inhalation route for treatment of respiratory diseases has the ability to deliver drugs, hormones, nucleic acids, steroids, proteins, and peptides, particularly to the site of action, improving the efficacy of the treatment and consequently lessening adverse effects of the treatment. Numerous inhalation delivery systems have been developed and studied to treat respiratory diseases such as asthma, COPD, and other pulmonary infections. The progress of disciplines such as biomaterials science, nanotechnology, particle engineering, molecular biology, and cell biology permits further improvement of the treatment capability...
2016: Journal of Drug Delivery
https://www.readbyqxmd.com/read/27864676/anti-ige-and-biologic-approaches-for-the-treatment-of-asthma
#10
Patrick D Mitchell, Amani I El-Gammal, Paul M O'Byrne
Current asthma treatments are effective for the majority of patients with mild-to-moderate disease. However, in those with more severe refractory asthma, agents other than inhaled corticosteroids and beta-agonists are needed both to better manage this group of patients and to avoid the side effects of high-dose corticosteroids and the social and personal hardship endured. Several biological pathways have been targeted over the last 20 years, and this research has resulted in pharmacological approaches to attempt to better treat patients with severe refractory asthma...
November 19, 2016: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/27860472/-cellular-and-molecular-mechanisms-of-action-of-bitter-compounds-recent-knowledge-and-perspective
#11
Milan Nagy, Pavel Mučaji
This overview paper describes in its introductory part bitter-tasting herbal drugs in the context of their traditional use in the loss of appetite and digestive disorders. Then, it mentions current knowledge on signals origin in bitter taste receptors leading to different, unexpected physiological processes. Newly observed biological effects of bitter tastants are correlated with modern trends of their complex study with an aim to develop new drugs primarily acting on bitter taste receptors.Key words: T2R bitter taste receptors GPCR bitters glucose homeostasis asthma ghrelin GLP-1 solitary chemosensory cells...
2016: Ceská a Slovenská Farmacie
https://www.readbyqxmd.com/read/27852121/preventive-intra-oral-treatment-of-sea-cucumber-ameliorate-ova-induced-allergic-airway-inflammation
#12
Da-In Lee, Mi-Kyung Park, Shin Ae Kang, Jun-Ho Choi, Seok-Jung Kang, Jeong-Yeol Lee, Hak Sun Yu
Sea cucumber extracts have potent biological effects, including anti-viral, anti-cancer, antibacterial, anti-oxidant, and anti-inflammation effects. To understand their anti-asthma effects, we induced allergic airway inflammation in mice after 7 oral administrations of the extract. The hyper-responsiveness value in mice with ovalbumin (OVA)-alum-induced asthma after oral injection of sea cucumber extracts was significantly lower than that in the OVA-alum-induced asthma group. In addition, the number of eosinophils in the lungs of asthma-induced mice pre-treated with sea cucumber extract was significantly decreased compared to that of PBS pre-treated mice...
November 16, 2016: American Journal of Chinese Medicine
https://www.readbyqxmd.com/read/27842891/a2b-adenosine-receptor-antagonists-design-synthesis-and-biological-evaluation-of-novel-xanthine-derivatives
#13
Sujay Basu, Dinesh A Barawkar, Vidya Ramdas, Yogesh Waman, Meena Patel, Anil Panmand, Santosh Kumar, Sachin Thorat, Rajesh Bonagiri, Dilip Jadhav, Partha Mukhopadhyay, Vandna Prasad, B Srinivasa Reddy, Arnab Goswami, Sandhya Chaturvedi, Suraj Menon, Azfar Quraishi, Indraneel Ghosh, Sushant Dusange, Shalini Paliwal, Abhay Kulkarni, Vikas Karande, Rhishikesh Thakre, Gaurav Bedse, Sreekanth Rouduri, Jayasagar Gundu, Venkata P Palle, Anita Chugh, Kasim A Mookhtiar
A2BAdoR is a low affinity adenosine receptor that functions by Gs mediated elevation of cAMP and subsequent downstream signaling. The receptor has been implicated in lung inflammatory disorders like COPD and asthma. Several potent and selective A2BAdoR antagonists have been reported in literature, however most of the compounds suffer from poor pharmacokinetic profile. Therefore, with the aim to identify novel, potent and selective A2BAdoR antagonists with improved pharmacokinetic properties, we first explored more constrained form of MRS-1754 (4)...
November 8, 2016: European Journal of Medicinal Chemistry
https://www.readbyqxmd.com/read/27836541/substituted-e-2-2-benzylidenehydrazinyl-4-methylthiazole-5-carboxylates-as-dual-inhibitors-of-15-lipoxygenase-carbonic-anhydrase-ii-synthesis-biological-evaluation-and-docking-studies
#14
Aamer Saeed, Shafi Ullah Khan, Parvez Ali Mahesar, Pervaiz Ali Channar, Ghulam Shabir, Jamshed Iqbal
15-Lipoxygenase (15-LOX) plays a major role in many inflammatory lung diseases including chronic obstructive pulmonary disease (COPD), asthma and chronic bronchitis. Over-expression of 15-LOX is related with some specific carcinomas including pancreatic, gastric and brain tumor. Similarly among different isozymes of carbonic anhydrase (CA), CA II is expressed in pancreatic, gastric carcinomas as well as in brain tumors. Therefore, novel potent inhibitors of both 15-LOX and CA II are required to explore the role of these enzymes further and to enable the drug discovery efforts...
November 8, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/27834175/severe-asthma-anti-ige-or-anti-il-5
#15
REVIEW
Evgenia Papathanassiou, Stelios Loukides, Petros Bakakos
Severe asthma is a discrete clinical entity characterised by recurrent exacerbations, reduced quality of life and poor asthma control as ordinary treatment regimens remain inadequate. Difficulty in managing severe asthma derives partly from the multiple existing phenotypes and our inability to recognise them. Though the exact pathogenetic pathway of severe allergic asthma remains unclear, it is known that numerous inflammatory cells and cytokines are involved, and eosinophils represent a key inflammatory cell mediator...
2016: European Clinical Respiratory Journal
https://www.readbyqxmd.com/read/27832763/a-comparison-of-intestinal-microbiota-in-a-population-of-low-risk-infants-exposed-and-not-exposed-to-intrapartum-antibiotics-the-baby-microbiota-of-the-intestine-cohort-study-protocol
#16
Julia Simioni, Eileen K Hutton, Elizabeth Gunn, Alison C Holloway, Jennifer C Stearns, Helen McDonald, Andrea Mousseau, Jonathan D Schertzer, Elyanne M Ratcliffe, Lehana Thabane, Michael G Surette, Katherine M Morrison
BACKGROUND: The intestinal microbiota influences metabolic, nutritional, and immunologic processes and has been associated with a broad range of adverse health outcomes including asthma, obesity and Type 2 diabetes. Early life exposures may alter the course of gut microbial colonization leading to differences in metabolic and immune regulation throughout life. Although approximately 50 % of low-risk full-term infants born in Canada are exposed to intrapartum antibiotics, little is known about the influence of this common prophylactic treatment on the developing neonatal intestinal microbiota...
November 10, 2016: BMC Pediatrics
https://www.readbyqxmd.com/read/27826957/development-of-new-therapies-for-severe-asthma
#17
REVIEW
Merritt L Fajt, Sally E Wenzel
Persistent asthma has long been treated with inhaled corticosteroids (CSs), as the mainstay of therapy. However, their efficacy in patients with more severe disease is limited, which led to the incorporation of poor response to ICSs (and thereby use of high doses of ICS) into recent definitions of severe asthma. Several studies have suggested that severe asthma might consist of several different phenotypes, each with ongoing symptoms and health care utilization, despite the use of high doses of ICS, usually in combination with a second or third controller...
January 2017: Allergy, Asthma & Immunology Research
https://www.readbyqxmd.com/read/27826220/chitinase-3-like-1-is-produced-by-human-th17-cells-and-correlates-with-the-level-of-inflammation-in-juvenile-idiopathic-arthritis-patients
#18
Manuela Capone, Laura Maggi, Veronica Santarlasci, Maria Caterina Rossi, Alessio Mazzoni, Gianni Montaini, Rolando Cimaz, Matteo Ramazzotti, Marie Pierre Piccinni, Giusi Barra, Raffaele De Palma, Francesco Liotta, Enrico Maggi, Sergio Romagnani, Francesco Annunziato, Lorenzo Cosmi
BACKGROUND: CHI3L1 is a chitinase-like protein without enzymatic activity, produced by activated macrophages, chondrocytes, neutrophils. Recent studies on arthritis, asthma, and inflammatory bowel diseases suggest that chitinases are important in inflammatory processes and tissue remodeling, but their production by human T cells, has never been reported. METHODS: A microarray analysis of gene expression profile was performed on Th17 and classic Th1 cell clones and CHI3L1 was found among the up-regulated genes on Th17 cells...
2016: Clinical and Molecular Allergy: CMA
https://www.readbyqxmd.com/read/27820746/role-of-biologics-targeting-type-2-airway-inflammation-in-asthma-what-have-we-learned-so-far
#19
Amit D Parulekar, Zuzana Diamant, Nicola A Hanania
PURPOSE OF REVIEW: Severe asthma is a heterogeneous syndrome that can be classified into distinct phenotypes and endotypes. In the type 2 (T2)-high endotype, multiple cytokines are produced that lead to eosinophilic inflammation. These cytokines and their receptors are targets for biologic therapies in patients with severe asthma who do not respond well to standard therapy with inhaled corticosteroids. RECENT FINDINGS: In the last decade, an increasing number of biologic therapies have been developed targeting T2 inflammation...
January 2017: Current Opinion in Pulmonary Medicine
https://www.readbyqxmd.com/read/27820745/role-of-sputum-biomarkers-in-the-management-of-asthma
#20
Sven F Seys
PURPOSE OF REVIEW: Airway inflammation is considered to be a cardinal feature of asthma. However, the type of airway inflammation is heterogeneous and airway inflammation may even be absent. Biomarkers may help to identify the inflammatory phenotype or endotype, especially now the time has come that targeted therapies enter daily practice. RECENT FINDINGS: Sputum biomarkers have increased our insights into the different inflammatory asthma phenotypes, their response to treatment and their association with progression of disease...
January 2017: Current Opinion in Pulmonary Medicine
keyword
keyword
51753
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"